NEW YORK (GenomeWeb News) — Epitome Biosystems has received a $500,000 Phase IIB Small Business Innovation Research grant from the National Science foundation, the company said today.
Epitome will use the cash to help it develop a technology that measures ”key tyrosine phosphorylation sites that have important roles in many cellular and drug responses,” the company said.
The technology is an antibody array that incorporates Epitome's EpiTag platform to enable researchers to qualitatively and quantitatively measure protein phosphorylation.
The firm won a Phase II SBIR grant, also for $500,000, in October 2005 that it used to develop a protein kinase that profiles cell-signaling pathways.
President Neal Gordon said the company’s products may help pharmas to develop drugs targeting diseases with abnormal signaling, such as kinase inhibitors.